305 452

Cited 56 times in

A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome

 Je-Hwan Lee  ;  Jun Ho Jang  ;  Jinny Park  ;  Seonyang Park  ;  Young-Don Joo  ;  Yeo-Kyeoung Kim  ;  Hoon-Gu Kim  ;  Chul Won Choi  ;  Sung-Hyun Kim  ;  Seong Kyu Park  ;  Eunkyung Park  ;  Yoo Hong Min 
 HAEMATOLOGICA, Vol.96(10) : 1441-1447, 2011 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/adverse effects ; Antimetabolites, Antineoplastic/therapeutic use* ; Azacitidine/adverse effects ; Azacitidine/analogs & derivatives* ; Azacitidine/therapeutic use ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; MyelodysplasticSyndromes/diagnosis ; MyelodysplasticSyndromes/drug therapy* ; MyelodysplasticSyndromes/mortality ; Prognosis ; ProspectiveStudies ; Republic of Korea ; Transplantation, Homologous ; TreatmentOutcome ; Young Adult
MDS, decitabine ; observational study
BACKGROUND: Decitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic syndrome with IPSS score of 0.5 or over.

DESIGN AND METHODS: Decitabine 20 mg/m(2)/day was given intravenously over one hour for five consecutive days every four weeks. The primary end point was overall response rate.

RESULTS: A total of 101 patients were analyzed. The International Prognostic Scoring System risk category was Intermediate-2/High in 47.5%. A median of 5 courses (range 1-18) were delivered. The overall response rate was 55.4% (13 complete responses, one partial response, 23 marrow complete responses, and 19 hematologic improvements). Forty-eight patients (47.5%) showed some hematologic improvement. With a median follow-up duration of 478 days (range 69-595), median overall survival was 17.7 months. Patients who showed hematologic improvement had significantly longer overall survival than those who did not (19.2 vs. 15.9 months, P=0.006 by landmark analysis at six months). The difference in overall survival was evident in the Intermediate-2/High risk group but not in the Intermediate-1 risk group. The progression-free survival and acute myeloid leukemia-free survival were 61.9% and 77.9% at one year, respectively. Among 489 assessable treatment courses, there were 97 fever episodes requiring intravenous antimicrobials.

CONCLUSIONS: Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement.
Files in This Item:
T201103465.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.